Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | SHFS 0.1324 -61.39% | XXII 0.1977 -8.34% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | RBNE 0.19 -2.56% | YFOR 0.2236 -1.58% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | TQQQ 66.29 -0.20% | TSLL 9.76 -1.21% | VZ 44.66 -1.19% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | GRAB 2.79 -2.11% | AIOK 12.02 182.82% | SQQQ 39.68 0.20% | ONDS 6.2 2.99% | LABT 0.31 -36.67% | AAPL 347.725 -0.14% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | IREN 24.905 -2.37% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | NFLX 65.85 -1.79% | QID 14.55 0.14% | CLRO 3.25 69.27% | WULF 11.32 0.00%
CECelcuity Inc. logo

Celcuity Inc. (CELC)

NASDAQ · Currency in USD
$65.25 ▼ -0.32 (-0.49%)
At close: Oct 23, 4:00 PM ET. Market closed.
$64.34 ▼ -0.91 (-1.39%)
After hours: Oct 23, 7:55 PM ET

Summary

Previous Close
$65.57
Open
$65.57
Day's Range
$63.49 – $66.29
52 Week Range
$53.54 – $151.02
Volume
1,316,079
Avg. Volume
1,345,468
Market Cap
$3.19B
Beta (5Y Monthly)
0.16
PE Ratio (TTM)
--
EPS (TTM)
-$4.13
Earnings Date
Nov 11, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$157.67

Profile: Celcuity Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
155
CEO
Brian F. Sullivan

Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it.

Earnings

Next report: Wed, Nov 11, 2026
EPS estimate -$1.50 · Revenue est. $1.60M
DateEst.Actual
Aug 13, 2026-$1.16-$1.44Miss
May 14, 2026-$1.04-$0.97Beat
Mar 25, 2026-$1.06-$0.97Beat
Nov 12, 2025-$1.02-$0.92Beat
Aug 14, 2025-$0.90-$1.04Miss
May 14, 2025-$0.95-$0.86Beat

Analyst view

Consensus price target
$157.67 ▲ +141.6%
Range $140.00 – $178.00
Rating: Buy
Buy 100% · Hold 0% · Sell 0%

Get free alerts on CELC and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.